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ABSTRACT 
The insilico methods for drug discovery are becoming increasingly powerful and useful. That in combination with increasing computer processor 
power. Lung cancer is the leading cause of cancer associated deaths Worldwide and has one of the poorest prognoses among all cancer types. A 
variety of melanoma antigen A (MAGE-A) genes are commonly detected in non-small cell lung cancers. Their biological function is not well 
characterized but may involve the regulation of apoptosis and cell cycle progression. In this study ligand-based drug design were employed to 
design novel MAGE inhibitors from Naringi crenulata found in  Asia. The MAGE structure model was built in homology modeling based on known 
receptors of the same family.  A phytochemicals of Naringi crenulata are analysed and optimized with the Argus lab to investigate the interactions 
between the target compounds and the amino acid residues of the Mage protein .All the compound have shown binding pose between from – 6.54 to 
-15.34.out of five compound 1,2-benzenedicarboxylic acid show best ligand energy -8.15Kcal/mol with  3 hydrogen  bond  of distance is 2.1,3.0 and 
2.3              
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INTRODUCTION  
Cancer is a pathological state involving uncontrolled proliferation of 
tumor cells. Though, it is one of the most dangerous diseases in 
humans and presently there is a considerable scientific discovery of 
new anticancer agents from natural products [1]. However, the 
drugs used for this therapy have a narrow therapeutic index, and 
often the responses produced are only just palliative as well as 
unpredictable. In contrast, targeted therapy that has been 
introduced in recent years is directed against  cancer-specific 
molecules and signaling pathways and thus has more limited 
nonspecific toxicities[2]   Lung cancer was a rare disease at the start 
of 20th century, but exposures to new etiologic agents. While 
tobacco had been widely used throughout the world for centuries, 
the present pandemic of lung cancer followed the introduction of 
manufactured cigarettes with addictive properties, which resulted in 
a new pattern of sustained exposure of the lung to inhaled 
carcinogen[3].Lung cancer occurs in multiple histologic types as 
classified by conventional light microscopy. The four major types 
include squamous cell carcinoma, adenocarcinoma, large cell 
carcinoma, and small cell undifferentiated carcinoma. Together, 
these four types of lung cancer account for > 90% of lung cancer 
cases in the United States [4] Melanoma-associated gene expression 
(MAGE) antigens were first described in a melanoma cell line. This is 
a 12-member family of proteins encoded on chromosome Xq28. The 
precise cellular expression and biological functions of the MAGE 
antigens have not been completely elucidated. Also referred to as 
‘cancer–testis antigens’, they are not expressed in normal tissues 
except the testis and placenta. In neoplastic lesions, they have been 
found to be expressed in 12–60% of solid malignant tumors 
including lung [5]. Type 1 MAGE expression has been documented in 
a broad variety of malignancies [6, 7]. Non–small cell lung cancers 
frequently express a variety of type 1 MAGE genes [8]. Proteasomal 
degradation of type 1 MAGE proteins generates several small 
peptides, which are subsequently expressed on the cell surface in 
association with MHC class I molecules. These peptides represent 
the target antigens for CTLs directed against MAGE-A-expressing 
cancer cells [9, 10– 11]. Based on these observations, type 1 MAGE 
protein–derived peptides are currently studied as targets for the 
development of cancer vaccines for non–small cell lung cancer and 
other malignancies [11]. 
 
 
MATERIALS AND METHODS  
Swiss Prot Database  
Swiss-Prot is a manually curated biological database of protein 
sequences. Swiss-Prot strives to provide reliable protein sequences 
associated with a high level of annotation, a minimal level of 
redundancy and high level of integration with other databases.  
Homology modeling  
Among all current theoretical approaches, comparative modeling is 
the only method that can reliably generate a 3D model of a protein 
from its amino acid sequence. Modeling of protein structures usually 
requires extensive expertise in structural biology and the use of 
highly specialized computer programs for each of the individual 
steps of the modeling process.[12]The method of homology 
modeling is based on the observation that protein tertiary structure 
is better conserved than amino acid sequence[13] The three 
dimensional structure of MAGE has been predicted using 
MODELLER9v8  
(http://www.salilab.org/modeller/) 
Model refinements and evaluation  
The model generated by MODELLER9v8 was subjected to energy 
minimization using the steepest descent technique to eliminate bad 
contacts between protein atoms using swiss pdb viewer. Validation 
of modelled structure was carried out using Structure Analysis and 
Validation Server. It performs structure validation calculations using 
PROCHECK, PROVE, Verify3D, ERRAT and WHAT_IF programs. The 
validated result of the modeled protein from the server is an 
important part of comparative modeling process.  
Active site prediction  
After obtaining the final model, the possible binding sites of short 
neurotoxin were searched using Computed Atlas of Surface 
Topography of Proteins (CASTp). These include pockets located on 
protein surfaces and voids buried in  the interior of proteins. CASTp 
includes a graphical user interface, flexible interactive visualization,  
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as well as on-the-fly calculation for user uploaded structures [14] 
Docking 
Docking the inhibitors against the active site of the MAGE Docking is 
a computational technique that samples conformations of small 
molecules in protein binding sites; scoring functions are used to 
assess which of these conformations best complements the protein 
binding site[15].The inhibitor and target protein was geometrically 
optimized and docked using docking engine Argus Dock. 
RESULTS AND DISCUSSION 
Molecular modeling (docking) study was carried out for compound 
like from Dioctyl phthalate, n-hexadecanoiac acid, Lupenone, 7-
tetradecenal,(z)-and 1,2-benzenedicarboxylic acid from Naringi 












Fig -1a, 1b, 1c, 1d, 1e: It Shows compound from Naringi 
crenulata plant Dioctyl phthalate, n-hexadecanoiac acid , Lupenone, 
7-tetradecenal,(z)- And 1,2 benzenedicarboxylic acid   
The potential active site amino acids were predicted using Castp. 
Among the 32 active sites predicted, pocket 1 found to be the best 
active site which contains 58 amino acids. Thus, the protein was 
targeted against pocket 1.Given the three-dimensional structure of a 
target receptor molecule usually a protein; chemical compounds 
having potential affinity towards it are designed rationally, with the 
aid of computational methods (Ooms,   2000). Figure 2 shows the 
structure of inhibitors target against the mage. 
 
Fig. 2: Shows the Structure Targeted Mage Protein Predicted 
Using Castp 
The target protein and inhibitors were geometrically optimized 
.Given the three-dimensional structure of a target receptor molecule 
usually a protein; chemical compounds having potential affinity 
toward sit are designed rationally, with the aid of computational 
methods. Detailed bioinformatics analysis offers a convenient 
methodology for efficient in silico preliminary analysis of possible 
function of new drug. Figure 3 shows the structure MAGE protein.  
 
Fig. 3: Shows the structure MAGE protein visualised using pyMol 
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MAGE protein was subjected to homology search against PDB 
database using BlastP to identify significant structural homologs to 
be used as template for homology modelling. The results indicated 
the presence of MAGE super family domain and the best homolog 
was Model with 40 % identity with the query protein and thus 
served as a template for modelling and the modelled protein 
obtained is shown in Fig5 and Validation was done using 
Ramachandran map (Fig.3) after loop refinement. 
All the five inhibitors were docked against active site of the target 
protein using Argus lab which gives an insight into the binding 
modes for the various inhibitors. Out of 5 inhibitors analyzed i.e. 
Dioctyl phthalate, n-hexadecanoiac acid, Lupenone, 1, 2-
benzenedicarboxylic acid, 7-tetradecenal,(z)-.  1,2-
benzenedicarboxylic acid has showed higher binding energy of 9.15 
Kcal/mol against the target protein. The binding energy of all the 
inhibitors was shown in Table 1. Figure 4 represents the docked 
complex of the inhibitors to that of the target protein. 
 
Fig.5: Ramachandran plot of Mage 
Table 1: It shows the Docking results of Naringi crenulata derived compounds against MAGE protein 
SI.NO Drug name Binding energy Distance Of Hydrogen bonding No. of Hydrogen Bonding 
1 1,2-benzenedicarboxylic acid -8.15Kcal/mol 2.1,3.0,2.3 03 
2 Lupenone -15.34Kcal/mol 3.4 01 
3 n-hexadecanoiac acid -6.14 Kcal/mol 2.9 01 
4 7-tetradecenal,(z)- -7.12 - - 
5 Dioctyl phthalate -6.54 - - 
Docking complex of Mage protein and 1,2-benzenedicarboxylic 
acid 
 
Fig. 4: Represents the Docked Complex of the Inhibitors to that 
of the Target Protein. 
The Table 2 describes the molecular property of 1,2-
benzenedicarboxylic acid (Table 2). 1,2-benzenedicarboxylic acid is 
a small sized molecule with a molecular weight of 166.13084  Da. It 
has two hydrogen bond donors and four hydrogen bond acceptors 
with two rotatable bond. The compound 1,2-benzenedicarboxylic 
acid has the LogP value of 0.7.Thereby it satisfies all the criteria of 
Lipinski's rule of five (Christopher et al., 1997). 
Table 2: Molecular property of 1,2-benzenedicarboxylic acid 
Molecular formula    C8H6O4 
Formula weight     166.13084   [g/mol]       
A logp                  0.7 
No. of hydrogen acceptors 04 
No. of hydrogen donors 02  
Density   1.593 g/cm3 
Polarizability 0.148185A3 
Monoisotopic mass       166.026609 Da 
Average mass           166.130798 Da 
CONCLUSIONS 
The present study indicates that the herbal plant Naringi crenulata  
can be used in the treatment of Lung cancer, which shows a strong 
binding affinity towards MEGA protein . This brings a strong focus 
towards these plant that, when administered during the treatment of 
lung cancer may block MEGA. Naringi crenulata showed the highest 
affinity towards MEGA compared to other compounds. This creates a 
strong hypothesis that the effects of complex formation by MEGA  
 
and Naringi crenulata contribute towards combating against Lung 
Cancer. Hence, MEGA PROTEIN may become a prospective target for 
inhibition of Lung cancer and may unlock a strong initiative in 
developing novel ligand which is specified towards it. Hence the 
compound specified in this work can undergo certain specification 
to improve its drug properties and could act as a best drug for lung 
cancer. The mechanism of action is lupenone to inhibit the activity of 
Mega that is involved in tumor proliferation 
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